March 28, 2018 8:28am
BLUE closed down -$13.75 and is up pre-market +$4.30 or +2.45%– BUY
bluebird bio (BLUE) and Celgene Corporation (CELG) have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States.
The companies originally entered into broad, global strategic research collaboration in 2013 to discover, develop and commercialize novel therapies in oncology, which included bb2121.
Just what BLUE needed after suffering the pangs of a downward slide ...